Payment overview · 2025
General Payments
$255.54
11 reported records · 6 companies
Healthcare provider profile · identity verified
Steven M Brown, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MINDEN, NV · NPI 1659459873
Verified facts
What the public records show
CMS Open Payments records show Steven M Brown, MD received $255.54 in general payments during 2025 across 11 reported records.
Stryker Corporation accounted for 36.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $93.48 | 36.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.32 | 18.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.84 | 16.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.11 | 13.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.82 | 9.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.97 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $255.54 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $59.12 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.32 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.11 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.11 | 2 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $34.36 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $29.92 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $27.28 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 527 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 507 | 161 |
| Levothyroxine Sodium | Levothyroxine Sodium | 400 | 109 |
| Lisinopril | Lisinopril | 379 | 115 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 331 | 129 |
| Losartan Potassium | Losartan Potassium | 246 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 69 |
| Telmisartan | Telmisartan | 212 | 86 |
| Gabapentin | Gabapentin | 198 | 71 |
| Metformin Hcl | Metformin Hcl | 183 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 148 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 44 |
| Omeprazole | Omeprazole | 133 | 42 |
| Trazodone Hcl | Trazodone Hcl | 131 | 42 |
| Meloxicam | Meloxicam | 127 | 59 |
| Furosemide | Furosemide | 125 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 36 |
| Simvastatin | Simvastatin | 109 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 34 |
| Finasteride | Finasteride | 97 | 32 |
| Eliquis | Apixaban | 95 | 32 |
| Tramadol Hcl | Tramadol Hcl | 78 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 27 |
| Famotidine | Famotidine | 74 | 26 |
| Potassium Chloride | Potassium Chloride | 71 | 26 |
| Donepezil Hcl | Donepezil Hcl | 66 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 18 |
| Sertraline Hcl | Sertraline Hcl | 65 | 20 |
| Lansoprazole | Lansoprazole | 58 | 23 |
| Atenolol | Atenolol | 57 | 22 |
| Carvedilol | Carvedilol | 57 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 16 |
| Montelukast Sodium | Montelukast Sodium | 57 | 17 |
| Allopurinol | Allopurinol | 54 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 54 | 20 |
| Metformin Hcl Er | Metformin Hcl | 50 | 21 |
| Buspirone Hcl | Buspirone Hcl | 49 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 39 |
| Pregabalin | Pregabalin | 45 | suppressed |
| Methylprednisolone | Methylprednisolone | 44 | 28 |
| Baclofen | Baclofen | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 42 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 14 |
| Ibuprofen | Ibuprofen | 41 | 19 |
| Januvia | Sitagliptin Phosphate | 41 | 12 |
| Lovastatin | Lovastatin | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 13 |
| Alendronate Sodium | Alendronate Sodium | 39 | 14 |
| Glipizide | Glipizide | 39 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Prednisone | Prednisone | 30 | 11 |
| Acyclovir | Acyclovir | 29 | 11 |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Azithromycin | Azithromycin | 27 | 25 |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | 11 |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Brilinta | Ticagrelor | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Tivicay | Dolutegravir Sodium | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $255.54 · 11 records | Stryker Corporation | AIRSUPRA, AREXVY, ARTIX MT, CLOTTRIEVER BOLD CATHETER, FLOWTRIEVER, Ozempic, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error